Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin + roxadustat for acquired pure red cell aplasia
ChiCTR2200065107Phase 3Recruiting
- Sponsor
- Suzhou Hongci Hematology Hospital
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sirolimus and roxadustat in pure red cell aplasia (PRCA), sponsored by Suzhou Hongci Hematology Hospital. Primary endpoint: Hemoglobin level at 6 months. Started Nov 2022; status: recruiting.
02
Drugs
sirolimusroxadustat
03
Conditions
pure red cell aplasia (PRCA)
Beyond the preview
Go deeper on ChiCTR2200065107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065107.